FIGURE 4.

Effects of subchronic administration of bergapten (BG) on scopolamine-induced impairment of memory acquisition trial (A) and consolidation trial (B) using the PA test in mice. Bergapten (12.5 mg/kg, i.p.) was administered 6 days twice daily. On the seventh day bergapten was administered 30 min and scopolamine (SCOP, 1 mg/kg, i.p.) 20 min before the first trial (A) or bergapten was administered immediately after first trial and scopolamine 10 min after bergapten injection (B) and animals were re-tested 24 h after the last injection; n = 8–12; the means ± SEM; *p < 0.05; ***p < 0.01 vs. saline-treated control group, ^##p < 0.01 vs. scopolamine-treated control group; ^^^p < 0.001 vs. bergapten-treated (12.5 mg/kg) group; Bonferroni’s test.